Wall Street brokerages expect Equillium (NYSE:EQ) to report ($0.34) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Equillium’s earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.44). The firm is expected to report its next quarterly earnings results on Monday, August 12th.
On average, analysts expect that Equillium will report full-year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($2.05) to ($1.09). For the next fiscal year, analysts expect that the company will post earnings of ($1.84) per share, with EPS estimates ranging from ($2.83) to ($1.34). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Equillium.
Equillium (NYSE:EQ) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04).
Shares of Equillium stock traded up $0.06 on Monday, reaching $5.51. The stock had a trading volume of 15,195 shares, compared to its average volume of 28,808. The firm’s 50 day moving average price is $5.87. Equillium has a 1 year low of $5.12 and a 1 year high of $19.69.
A number of hedge funds and other institutional investors have recently made changes to their positions in EQ. Partner Fund Management L.P. purchased a new position in shares of Equillium during the 4th quarter valued at approximately $11,049,000. Victory Capital Management Inc. increased its holdings in shares of Equillium by 7.4% during the 1st quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after purchasing an additional 90,792 shares in the last quarter. FMR LLC purchased a new position in shares of Equillium during the 4th quarter valued at approximately $6,994,000. BlackRock Inc. purchased a new stake in Equillium in the 4th quarter worth $1,756,000. Finally, Northern Trust Corp purchased a new stake in Equillium in the 4th quarter worth $298,000.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.